As a first step toward evaluating whether PARP7 levels in human prostate cancer are potentially actionable with RBN2397, we analyzed PARP7 gene expression data from primary prostate tumors and metastatic AR+ and AR− prostate tumors (17). This evidence concerns the gene AR and prostate carcinoma.